References
Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104:1534–41.
de la Torre-Aláez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI, Rodriguez-Fraile M, Sancho L, et al. The pattern of progression defines post-progression survival in patients with hepatocellular carcinoma treated with SIRT. Cardiovasc Interv Radiol. 2020;12:1–8.
Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatol. 2013;58:2023–31.
Rincón JO, Regi AR, Leyte MG, Martín LC, Pascual RP, Farto JCA. Hepatic supraselective radioembolization, today and new horizons. Eur J Nucl Med Mol Imaging. 2019;46:2412–3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nezami, N., Geschwind, JF.H. Predicting Patient Survival in Oncology: Is it Time to Take a New Path?. Cardiovasc Intervent Radiol 43, 1173–1174 (2020). https://doi.org/10.1007/s00270-020-02553-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-020-02553-y